Compare Nuwellis Inc (NUWE) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Under Armour Inc Class A — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while Under Armour Inc Class A trades at $4.74 (market cap $2.05B). The key difference: Under Armour Inc Class A is far larger — about 931.8× Nuwellis Inc's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Under Armour Inc Class A for 18 Days on average.
| NUWE | UA | |
|---|---|---|
Market Cap | $2.20M | $2.05B |
Volume | 121,544 | 3,002,780 |
Sector | Health | Consumer Cyclical |
52-Week High | $146.65 | $7.88 |
52-Week Low | $0.68 | $3.96 |
Typical Hold Time | 26 Days | 18 Days |
Enterprise Value | -$1.52M | $3.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Under Armour (UA) trades at $4.70, down 0.42% with a bearish technical outlook despite recent earnings beats. The company faces significant challenges with negative net income margins (-9.99%) and declining revenue trends, though it maintains a reasonable P/S ratio of 0.41. Recent quarterly results show mixed performance with two beats and one miss, while cash flow remains negative across all categories.
The stock presents high risk with deteriorating fundamentals and negative profitability metrics. While analyst sentiment leans slightly positive with 41% buy ratings, the company's revenue declines and negative cash flow position create substantial headwinds. Investment opportunity exists only for those betting on a successful turnaround strategy execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
